Cangene consolidates, cuts staff

Canada's Cangene announced that it is consolidating all R&D activities within the Winnipeg head office location and cutting its staff by 4 percent. Cangene says its consolidating in order to enhance new product development, strengthen the links between research, product development and manufacturing activities, and increase operational effectiveness. The company expects the new arrangement to save $1.5 million a year.

- see Cangene's release

Suggested Articles

Shorla Pharma picked up $8.3 million to push its cancer programs through U.S. regulatory approval and gear up for its first drug launch in 2021.

Nodthera bagged $55 million to get its lead asset through phase 1 and into proof-of-concept studies, and a second program into the clinic.

Genor Biopharma banked $160 million from the likes of Hillhouse and Temasek Holdings to advance its clinical-stage autoimmune and cancer programs.